AK Medical Holdings Limited disclosed a Next Day Disclosure Return dated 2 June 2026, confirming that its issued share capital remains unchanged at 1.12 billion ordinary shares with no treasury shares outstanding.

Between 6 February and 2 June 2026, the company repurchased a total of 11.47 million shares that are awaiting cancellation, equal to 1.02 % of current issued shares. The repurchase prices ranged from HKD 5.84 to HKD 7.00 per share.

The most recent transaction, completed on 2 June 2026, involved 1.07 million shares bought on the Hong Kong Stock Exchange at HKD 5.88–5.91 per share, for a total consideration of HKD 6.31 million. All 1.07 million shares are designated for cancellation.

The buybacks are conducted under a mandate approved on 18 June 2025, which authorises the repurchase of up to 112.27 million shares. Cumulative repurchases now stand at 11.47 million shares, utilising 10.22 % of the mandate. In line with listing rules, AK Medical is subject to a moratorium on issuing new shares or transferring treasury shares until 2 July 2026.

The company confirms that all repurchase activities were duly authorised by the board and executed in compliance with Hong Kong Listing Rules and other applicable regulations.